Pagliflozin Tablets 10mg (Dapagliflozin Monohydrate Mixture)
Dapagliflozin Anhydrous Lactose Mixture 15.27mg
Tablet · Prescription medication
AhnGuk Pharmaceutical Co., Ltd.
MFDS item code 202005370 · Approved 2020.07.23
This product's status changed to Expired on 2025.07.23. It may no longer be sold, so consult a doctor or pharmacist before taking it.
Improvement of glycemic control in type 2 diabetes mellitus
This medication is used as an adjunct to diet and exercise for the improvement of blood glucose control in patients with type 2 diabetes. It can be used alone or in combination with other diabetes medications. For example, it may be administered when glycemic control is difficult with metformin alone, and it supports blood sugar management when combined with other medications such as insulin or sitagliptin. Furthermore, it can be added to enhance therapeutic efficacy when satisfactory blood glucose control is not achieved with multiple medication combinations. It plays an important role in improving blood glucose control across various treatment scenarios.
Type 2 diabetes mellitus Monotherapy and add-on combination therapy The recommended dose of this medicine is 10mg once daily for monotherapy and add-on combination therapy with other glucose-lowering agents, such as insulin. When this medicine is used in combination with insulin or insulin secretagogues such as sulfonylureas, a lower dose of insulin or the insulin secretagogue may be considered to reduce the risk of hypoglycemia. Initial combination therapy For patients with no prior experience of diabetes medication, when administered in combination with metformin, the recommended initial dose of this medicine is 5mg once daily or 10mg once daily. Special populations Renal impairment - eGFR less than 45 mL/min/1.73m2: Use of this medicine is not recommended for the purpose of improving glycemic control. - Patients on dialysis: Do not administer this medicine. Hepatic impairment No dose adjustment is required for patients with mild or moderate hepatic impairment. For patients with severe hepatic impairment, 5 mg is recommended as the starting dose. If well tolerated, this dose may be increased to 10mg. Elderly patients (≥ 65 years) Dose adjustment based on age is not recommended. Method of administration This medicine may be taken orally once daily at any time of the day, with or without food. The tablet should be swallowed whole.
Pediatric patients The efficacy and safety of dapagliflozin in children under 18 years of age have not been established. No relevant data are available.
This medication should not be used in patients who have had an allergic reaction to the active ingredient or additives. It should not be administered to patients with type 1 diabetes or diabetic ketoacidosis. This medication contains anhydrous lactose, so it should not be given to patients with genetic disorders such as galactose intolerance, Lapp lactase deficiency, or glucose-galactose malabsorption. Patients undergoing renal dialysis should also not use this medication. It should be used cautiously in patients with decreased fluid volume or impaired kidney function, and attention should be paid to hypotension or changes in kidney function. In particular, elderly patients or those taking diuretics must closely monitor their blood pressure and fluid status. This medication contains colorants, Yellow No. 4 and Yellow No. 5, so those allergic to these components should exercise caution. The most common side effect of this medication is genital infections, which may occur more frequently in women. Hypoglycemic symptoms may occur more frequently when used with insulin or sulfonylureas, so blood glucose fluctuations should be carefully monitored. Dehydration or hypotension symptoms may result from decreased fluid volume, so hydration should be adequate, and medical consultation is advised if abnormal symptoms occur. Diabetic ketoacidosis may occur; thus, if symptoms such as vomiting, abdominal pain, or difficulty breathing arise, immediate hospital attention is necessary. The risk of urinary tract infections, including cystitis and pyelonephritis, may increase, so prompt treatment is necessary if pain or discomfort during urination occurs. In patients with reduced kidney function, creatinine levels may increase, necessitating regular blood tests. Severe infections such as perineal necrosis have been rarely reported, and patients should immediately inform medical personnel if pain, swelling, or fever around the genital area occurs. Pregnant or breastfeeding women should not use this medication, and treatment should be discontinued upon confirmation of pregnancy. The safety and efficacy of this medication in children have not been established, so it is not administered to this age group. In the case of overdose, specific antidotes are not available, so appropriate treatment should be administered according to symptoms. This medication may pose a risk of hypoglycemia when used with insulin or sulfonylureas, so dose adjustment and blood glucose monitoring are needed. Additionally, this medication does not significantly affect driving or machine operation, but caution should be exercised as hypoglycemic symptoms may occur.
Not everyone experiences these, and they can vary from person to person.
This medication should be stored in a tightly sealed container to prevent exposure to air and moisture. It is essential to maintain storage temperatures between 1°C and 30°C at room temperature. This ensures the medication's efficacy is preserved and prevents degradation.
Yellow, double-sided, convex, rhomboid film-coated tablets
28 tablets/box [7 tablets/PTP X 4]
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Dapagliflozin Anhydrous Lactose Mixture 15.27mg
Tablet · Prescription medication
AhnGuk Pharmaceutical Co., Ltd.
Dapagliflozin Anhydrous Lactose Mixture 7.635mg
Tablet · Prescription medication
International Pharmaceuticals Co., Ltd.

Dapagliflozin Anhydrous Lactose Mixture 15.27mg
Tablet · Prescription medication
International Pharmaceutical Co., Ltd.
Dapagliflozin Anhydrous Lactose Mixture 7.635mg
Tablet · Prescription medication
Shinil Pharmaceutical Co., Ltd.

Dapagliflozin Anhydrous Lactose Mixture 15.27mg
Tablet · Prescription medication
Sinil Pharmaceutical Co., Ltd.
Dapagliflozin Anhydrous Lactose Mixture 7.635mg
Tablet · Prescription medication
Dongwha Pharmaceutical Co., Ltd.

Dapagliflozin Anhydrous Lactose Mixture 15.27mg
Tablet · Prescription medication
Donghwa Pharmaceutical Co., Ltd.
Dapagliflozin Anhydrous Lactose Mixture 7.635mg
Tablet · Prescription medication
Albozen Korea Co., Ltd.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.